Other Vaccines - Haiti

Haiti

Highlights

In 2024, the projected revenue for the Other Vaccines market in Haiti is estimated to reach US$5.32m.
It is expected that the revenue will experience an annual growth rate of 10.08% from 2024 to 2029, resulting in a market volume of US$8.60m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Other Vaccines market in 2024, amounting to US$24.73bn.
Despite being a developing nation, Haiti has made significant progress in the development and distribution of other vaccines, improving public health outcomes.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Haiti has been steadily developing in recent years.

Customer preferences: Haiti has a high demand for vaccines due to its history of infectious diseases. The population has a high awareness of the importance of vaccination and seeks out vaccines to protect themselves and their families.

Trends in the market: The Other Vaccines market in Haiti has seen an increase in demand for vaccines that protect against diseases such as meningitis and pneumonia. This trend can be attributed to the country's high incidence of these diseases. Additionally, there has been a growing demand for vaccines that protect against diseases that are prevalent in neighboring countries, such as yellow fever.

Local special circumstances: Haiti is a low-income country with limited healthcare resources. The country also has a high incidence of infectious diseases, which makes vaccines a crucial part of the healthcare system. However, the country faces challenges in terms of vaccine distribution and access to healthcare, which can limit the availability of vaccines in certain areas.

Underlying macroeconomic factors: Haiti's economy has been struggling in recent years, which can limit the government's ability to invest in healthcare infrastructure and vaccine distribution. Additionally, the country has faced political instability, which can also impact the healthcare system. However, international aid and support from organizations such as UNICEF have helped to improve vaccine access in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.